Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects
with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma.
ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb. It binds to the
activated human T cells via a T cell receptor CD137. ADG106 administered intravenously (IV)
over a period of 60-90 minutes.
Primary objective:
To assess safety and tolerability at increasing dose levels of single agent ADG106 in
subjects with advanced or metastatic solid tumors and/or non Hodgkin lymphoma.
To determine the recommended dosage and dosage regimen for further study. Secondary
Objectives To characterize the pharmacokinetic (PK) profiles of ADG106. To evaluate the
immunogenicity of ADG106. To evaluate the potential anti-tumor effect of ADG106. To
investigate serum biomarkers related to immune regulation and cytokine releasing.
Exploratory Objective:
To identify the potential biomarkers of ADG106.